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Dr Valavanur Subramanian (New York, NY). Marc, congratu-
lations. Finally you are showing some patency data in the mix.
Here is the problem I have. We are now talking about what is
the best second arterial graft, because 2 arterial grafts are
important for long-term survival. It is a very low-risk group of
patients. Now you are advocating minimally invasive multivessel
grafting as a standard SVG as a LITA graft. How do you defend
your position going forward for the sake of just continuing the
SVG in this group of patients?
Dr Ruel. I didn’t hear all of your question, but I think you are
asking about the second and third arterial grafts. I agree with
you; however, there are 3 problems with CABG. First, we have
to make it a 0%mortality operation, and we are close to that, either
minimally invasively or open.
Second, we have to try to reach for 100% patency. We led the
Clopidogrel After Surgery for Coronary Artery Disease
(CASCADE) Trial before, and I would like to show some
discussion slides. Obviously with CASCADE, the 1-year
angiographic patency was extremely high. In CASCADE, even
the SVG patency in the hands of the Principal Investigators, Pierre
Voisine and I, was 96% at 1 year on angiograms. So this was
extremely high. We need to try to reach that confluence where
we have a perfect operation with zero risk.
There is a third problem with CABG, and it is its invasiveness,
which we also have to work on. What we have shown today is
not that MICS CABG is the perfect durable operation. I don’t think
we have the same results here as when doing LITA, right internal
thoracic artery, or radial on everyone, but we certainly have made
great strides with regard to decreasing the invasiveness of CABG.
The next step may be to take a right internal thoracic artery
down with a robot and give everyone bilateral thoracic arteries.
Now that we have shown that the patency of doing a proximal
on the aorta through a small incision is high, it is a leap forward
toward achieving that goal.
Dr Subramanian.We ought to be honest in comparing patency
with a gold standard, angiography, because validation with
computed tomography, as you have shown, Fitzgibbon score,
and anastomotic quality is not there. So I wish Medtronic had
supported you to do a good angiography study with the money
involved, and it’s important for us to do it.
Dr Ruel. Angiographic quality, first, is something you
can look at with computed tomography. It’s not always
perfect visualization, especially if the heart rate is more than
65 beats/min, but there can be good definition of the anastomosis
there. You also have to look at clinical outcomes; there was not a
single patient who needed revascularization, so a subradiologic
signal, if you will, is unlikely.
I too believe that when you add everything together, computed
tomography is not perfect. It actually will make some grafts not
easy to evaluate, especially if there are a lot of clips or lots of
motion. But angiography is not perfect either and can miss grafts.
Again, it is important that we do those patency trials. There is no
perfect way to assess patency, but it’s important to carry on and do
those, in my opinion.
Dr Nikolaos Bonaros (Innsbruck, Austria). The main charac-
teristic of your series is that you construct the proximalery c January 2014
Ruel et al Acquired Cardiovascular Diseaseanastomosis in the aorta and you do not do a Y or T graft. Can
you give us some insight as to how you make your decision if
you are doing a sequential anastomosis or an anastomosis to the
aorta?
Dr Ruel.We described our techniques in other articles, and it is
beyond the scope of today’s talk, but you are absolutely right.
What we generally do is 1 vein graft equals 1 proximal anasto-
mosis, and relatively few sequentials. The configuration one sees
on a computed tomography scan essentially is exactly the same
as the configuration would be after an open multivessel CABG.
There may be a way to maximize the use of sequential grafts
with this operation, but you can easily do up to 3 proximal
anastomoses on the ascending aorta with this technique.
The other defining feature is not just the proximals. In this
series, as you have seen, a lot of posterior descending arteriesThe Journal of Thoracic and Cawere grafted, obtuse marginals 3 and 2, and this is another level
of minimally invasive applicability that wasn’t seen before.
Dr Vivek Rao (Toronto, Canada). Marc, can you just clarify,
when you do pump assistance, is it femoral cannulation?
Dr Ruel. It is, yes.
Dr Rao. Any femoral complications from that?
Dr Ruel.No, there were not. Actually in the overall experience,
there are now more than 1000 patients in the series by Joe and me,
and we haven’t had serious peripheral vascular complications from
this operation.
These are obviously somewhat selected patients. If I see some-
one in whom I’m going to do 4 grafts, one of the first things I do in
clinic is to make sure that the femoral pulses are nice and bound-
ing, and that we are not going to perform a challenging multivessel
MICS CABG in someone who has a 3-mm external iliac vessel.rdiovascular Surgery c Volume 147, Number 1 209
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